These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20665426)

  • 1. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
    Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S
    Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
    Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
    Hohla F; Buchholz S; Schally AV; Krishan A; Rick FG; Szalontay L; Papadia A; Halmos G; Koster F; Aigner E; Datz C; Seitz S
    Cancer Lett; 2010 Aug; 294(1):35-42. PubMed ID: 20156671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
    Seitz S; Schally AV; Treszl A; Papadia A; Rick F; Szalontay L; Szepeshazi K; Ortmann O; Halmos G; Hohla F; Buchholz S
    Anticancer Drugs; 2009 Aug; 20(7):553-8. PubMed ID: 19491659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
    Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
    Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
    Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
    Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
    Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
    Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
    Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
    Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
    Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
    Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
    Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of cancer cell lines for peptide receptor-targeted drug development.
    Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH
    J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
    Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
    Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.